High Growth Tech Stocks To Watch In Hong Kong September 2024

The Hong Kong market has been experiencing notable fluctuations, with the Hang Seng Index recently giving up 0.43%, reflecting broader concerns about weak inflation data and economic stability in China. Amid these market dynamics, identifying high-growth tech stocks requires a focus on companies that demonstrate resilience and innovation in a rapidly evolving sector.

Top 10 High Growth Tech Companies In Hong Kong

Name	Revenue Growth	Earnings Growth	Growth Rating
Wasion Holdings	22.37%	25.47%	★★★★★☆
MedSci Healthcare Holdings	48.74%	48.78%	★★★★★☆
Inspur Digital Enterprise Technology	25.37%	39.10%	★★★★★☆
Cowell e Holdings	31.82%	35.43%	★★★★★★
RemeGen	26.30%	52.19%	★★★★★☆
Akeso	33.07%	54.67%	★★★★★★
Innovent Biologics	22.34%	59.40%	★★★★★☆
Biocytogen Pharmaceuticals (Beijing)	21.53%	109.17%	★★★★★☆
Beijing Airdoc Technology	37.47%	93.35%	★★★★★☆
Sichuan Kelun-Biotech Biopharmaceutical	24.70%	8.53%	★★★★★☆

Click here to see the full list of 45 stocks from our SEHK High Growth Tech and AI Stocks screener.

Let's uncover some gems from our specialized screener.

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a biopharmaceutical company involved in the research, development, manufacturing, and commercialization of novel drugs to address unmet medical needs in China and internationally, with a market cap of HK$41.25 billion.

Operations: Kelun-Biotech generates revenue primarily from its pharmaceuticals segment, which amounted to CN¥1.88 billion. The company focuses on developing novel drugs for unmet medical needs both in China and globally.

Sichuan Kelun-Biotech Biopharmaceutical has demonstrated significant growth with a 24.7% increase in revenue over the past year, reaching ¥1.38 billion. Their focus on R&D is evident, with substantial investments leading to promising advancements like sacituzumab tirumotecan (sac-TMT), which showed a median progression-free survival of 5.6 months versus 2.7 months for standard treatments in TNBC patients as of November 2023. The company's recent earnings report also highlighted a net income turnaround to ¥310 million from a prior loss, underscoring its potential within the biotech sector.

• Get an in-depth perspective on Sichuan Kelun-Biotech Biopharmaceutical's performance by reading our health report here.

• Evaluate Sichuan Kelun-Biotech Biopharmaceutical's historical performance by accessing our past performance report.

Tencent Holdings (SEHK:700)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Tencent Holdings Limited, an investment holding company, provides value-added services (VAS), online advertising, fintech, and business services in China and internationally with a market cap of HK$3.48 trillion.

Operations: Tencent Holdings Limited generates revenue primarily from value-added services (VAS), online advertising, and fintech and business services. For the most recent period, VAS contributed CN¥302.28 billion, fintech and business services CN¥209.17 billion, and online advertising CN¥111.89 billion to the total revenue.

Tencent Holdings has shown robust performance with a 12.82% forecasted annual earnings growth, outperforming the Hong Kong market's 11.7%. The company reported a significant rise in Q2 revenue to ¥161.12 billion from ¥149.21 billion last year, while net income surged to ¥47.63 billion from ¥26.17 billion, highlighting its strong operational efficiency and strategic initiatives in AI and cloud services sectors. Tencent's R&D expenses are substantial, reflecting its commitment to innovation; for instance, its recent investments have driven advancements in gaming and social media technologies.

• Click here to discover the nuances of Tencent Holdings with our detailed analytical health report.

• Learn about Tencent Holdings' historical performance.

Akeso (SEHK:9926)

Simply Wall St Growth Rating: ★★★★★★

Overview: Akeso, Inc. is a biopharmaceutical company that focuses on the research, development, manufacturing, and commercialization of antibody drugs with a market cap of HK$61.99 billion.

Operations: The company generates revenue primarily from the research, development, production, and sale of biopharmaceutical products, totaling CN¥1874.14 million. The business model centers around antibody drugs within the biopharma sector.

Akeso's recent advancements in oncology, particularly with ivonescimab, underscore its innovative edge in high-growth tech. The company's R&D expenses reflect a strong commitment to innovation, with notable investments driving significant progress. For instance, Akeso's revenue is expected to grow at 33.1% annually, outpacing the Hong Kong market's 7.3%. Despite a net loss of ¥238.59 million for H1 2024 compared to last year's ¥2.53 billion net income, the forecasted annual profit growth remains robust at 54.67%.

• Delve into the full analysis health report here for a deeper understanding of Akeso.

• Explore historical data to track Akeso's performance over time in our Past section.

Where To Now?

• Unlock our comprehensive list of 45 SEHK High Growth Tech and AI Stocks by clicking here.
• Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
• Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.

Ready For A Different Approach?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com